Treatment trajectories among children and adolescents referred to the Norwegian National Center for Gender Incongruence.

Autor: Nyquist CB; Division of Paediatric and Adolescent Medicine, Department of Child and Adolescent Mental Health in Hospitals, Oslo University Hospital, Oslo, Norway.; Division of Paediatric and Adolescent Medicine, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Torgersen L; Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway., David LW; Division of Paediatric and Adolescent Medicine, Department of Child and Adolescent Mental Health in Hospitals, Oslo University Hospital, Oslo, Norway.; Division of Paediatric and Adolescent Medicine, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Diseth TH; Division of Paediatric and Adolescent Medicine, Department of Child and Adolescent Mental Health in Hospitals, Oslo University Hospital, Oslo, Norway.; Division of Paediatric and Adolescent Medicine, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Gulbrandsen K; Department of Gender Identity Assessment, Norwegian National Center for Gender Incongruence, Oslo University Hospital, Oslo, Norway., Waehre A; Division of Paediatric and Adolescent Medicine, Department of Child and Adolescent Mental Health in Hospitals, Oslo University Hospital, Oslo, Norway.
Jazyk: angličtina
Zdroj: Acta paediatrica (Oslo, Norway : 1992) [Acta Paediatr] 2024 Dec 08. Date of Electronic Publication: 2024 Dec 08.
DOI: 10.1111/apa.17530
Abstrakt: Aim: We aimed to describe treatment trajectories, detransition and mortality rate among children and adolescents referred to the Norwegian National Center for Gender Incongruence (NCGI).
Methods: The cohort included all 1258 persons under 18 years at referral to the NCGI from 2000 to 2020. Trajectories were registered until end of 2023.
Results: In total, 861/1258 (68.4%) were assigned female gender at birth (AFAB). Mean age at referral was 14.4 years. Puberty suppression with gonadotropin-releasing hormone agonists (GnRHa) was initiated among 135/1258 (10.7%), significantly more persons assigned male gender at birth (AMAB) than AFAB (p < 0.001). Gender-affirming hormonal treatment (GAHT) was initiated in 783/1258 (62.2%). The continuation rate from GnRHa to GAHT was 97%. Discharge rate from NCGI without gender-affirming medical treatment among those who attended at least one appointment, was 264/1198 (22.0%). Eighteen AFAB detransitioned after initiated GAHT, eleven due to a cessation of transgender identity. Mortality rate in the cohort until end of 2023 was 11/1258 (0.9%).
Conclusion: Different trajectories including medical pathways and assessments without gender-affirming treatment were observed. GAHT was initiated in 783/1258 (62.2%), including eighteen AFAB detransitioning after testosterone treatment. There was a high continuation rate from GnRHa to GAHT. Various trajectories highlights the need for long-term follow-up in care.
(© 2024 The Author(s). Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica.)
Databáze: MEDLINE
Externí odkaz: